Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Rahul Ravindran has been awarded a highly competitive MRC Clinical Research Training Fellowship, following a successful research placement at the Kennedy Institute in 2019.

Rahul Ravindran portrait

The award provides support to Rahul as he investigates the biology of chronic inflammation in inflammatory bowel disease (IBD). He is one of 16 DPhil students to have joined the Institute this week as part of the 2020 student intake.

Prof Chris Buckley, Director of Clinical Research, said: "I am delighted Rahul is joining the Institute to pursue his DPhil on the role of the lymphatic endothelium in driving inflammation in IBD, with Prof Fiona Powrie and I supervising his work. He will also be collaborating with Prof David Jackson at the MRC Weatherall Institute of Molecular Medicine here in Oxford, as well as with Prof Gwen Randolph, Washington University, USA."

Rahul is one of a growing number of clinician scientists to recently join the Kennedy as part of the Institute's ambition in clinical science. "The Kennedy's approach of breaking down traditional clinical silos to deliver the cellular basis of inflammation now sees Rahul (gastroenterology) join Clinical Fellows studying for DPhils at the Kennedy from disciplines including oncology, haematology, ophthalmology, dermatology, cardiology and, of course, rheumatology," explained Chris.

Speaking of his award, Rahul said: "I had a fantastic experience at the Kennedy Institute during my Academic Clinical Fellowship, and I am delighted to have been awarded this MRC Fellowship in order to continue pursuing the work I started here. I am immensely grateful to my supervisors, Prof Chris Buckley and Prof Fiona Powrie, as well as to many other members of the Kennedy I have had the pleasure of working with and learning from."

Rahul first joined the Kennedy Institute in 2019 as part of his training as an Academic Clinical Fellow in Gastroenterology. During a six-month placement in Prof Fiona Powrie's laboratory, he helped recruit IBD patients to studies examining the role of stromal cells in inflammation. He also worked with postdoctoral scientists to isolate and image gut lymphatic endothelial cells and presented this work internationally, forming an exciting basis to further investigate their role in intestinal inflammation.

We wish Rahul every success during his DPhil training.

Similar stories

Wellcome Trust Investigator Award for Professor Arnon

Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.

The Kennedy Institute Student Symposium returns for its 5th year

A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.

Researchers from the Kennedy Institute awarded MRC funding

Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Major ERC funding awarded to Professor Michael Dustin

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.